It can selectively bind to VEGF and inhibit the binding of VEGF to FLT-1 and KDR on the surface of endothelial cells, resulting in the inability of endogenous VEGF to exert its biological activity, thus inhibiting the proliferation and migration of vascular endothelial cells, inducing endothelial cell apoptosis, inhibiting the formation of tumor angiogenesis, and promoting the existing abnormal regression vessels 52-53. The gene discussed is VEGFA; the disease is neoplasm.